SCHEMBL4773542

SCHEMBL4773542

COc1ccc(-c2cc3ncccc3c(=O)[nH]2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.59
CCNB2 O95067 2/20 0.58
CDK1 P06493 2/20 0.58
CCNB1 P14635 2/20 0.58
CCNB3 Q8WWL7 2/20 0.58
GSK3A P49840 1/20 0.58
GSK3B P49841 1/20 0.58
CDK5 Q00535 1/20 0.58
CDK5R1 Q15078 1/20 0.58
RIPK1 Q13546 1/20 0.56
TNKS O95271 3/20 0.54
TNKS2 Q9H2K2 2/20 0.54
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
GUSB P08236 1/20 0.54
CASP3 P42574 1/20 0.54
SENP7 Q9BQF6 1/20 0.54
SENP6 Q9GZR1 1/20 0.54
KDM4E B2RXH2 3/20 0.52
ALDH1A1 P00352 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15775696 0.85 TNKS (0.57) PARP1CCNB2CDK1CCNB1CCNB3
SCHEMBL8602417 0.83 ADORA2A (0.59) PARP1CCNB2CDK1CCNB1CCNB3
SCHEMBL15775264 0.82 RIPK1 (0.52) PARP1RIPK1TNKSTNKS2NPC1
SCHEMBL15775722 0.82 CCNB2 (0.55) PARP1CCNB2CDK1CCNB1CCNB3
SCHEMBL15775563 0.82 PARP1 (0.56) PARP1CCNB2CDK1CCNB1CCNB3
SCHEMBL15775268 0.82 CCNB2 (0.55) PARP1CCNB2CDK1CCNB1CCNB3
SCHEMBL4765770 0.78 RIPK1 (0.67) PARP1CCNB2CDK1CCNB1CCNB3
SCHEMBL15775369 0.78 TNKS (0.59) PARP1CCNB2CDK1CCNB1CCNB3
SCHEMBL7913613 0.78 ADORA2A (0.70) CCNB2CDK1CCNB1CCNB3GSK3A
SCHEMBL30472919 0.78 ADORA2A (0.70) CCNB2CDK1CCNB1CCNB3GSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014087165-A1 TANKYRASE INHIBITORS UNIVERSITY OF BATH (GB) 2014-06-12 WO disclosed
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. 2004-10-14 US disclosed
US-6790844-B2 MUSCLE RELAXANTS; ANTISEROTONINE AGENT EISAI CO., LTD (JP) 2004-09-14 US disclosed
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013460-A1 Condensed pyridine compound MUSK, HTR1A, PAX3 PARP1 1660/4885CCNB2 364/4885CDK1 150/4885
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives MUSK, HTR1A, RYR1 PARP1 1099/4885CCNB2 1277/4885CDK1 998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.